Answers are grounded in this paper and cite their sources.
NTRK-rearranged spindle cell tumors represent a distinct entity among kinase fusion-driven mesenchymal neoplasms, as recognized in the 5th edition of the WHO Classification of Soft Tissue and Bone Tumors. Histologically, these tumors exhibit a spectrum of morphological features ranging from lipofibromatosis-like to malignant peripheral nerve sheath tumor-like patterns, encompassing both low- and high-grade morphologies. A diagnostically useful microscopic feature is the presence of prominent keloid-like hyalinized collagen bands, which are often arranged in perivascular rings. Immunophenotypically, these tumors typically co-express S-100 and CD34, and show diffuse pan-TRK positivity. Genetically, most cases involve fusions of NTRK1 or NTRK3 with partners, such as LMNA , TPM3 , or TPR ; rearrangements involving NTRK2 are far less common. Herein, we report a rare case of high-grade spindle cell sarcoma harboring a TRIM25::NTRK2 fusion in an 84-year-old male who presented with facial radiculoneuralgia and a right submandibular mass. Histopathological evaluation revealed a poorly differentiated neoplasm with infiltrative growth, marked nuclear atypia, frequent mitosis, and extensive necrosis. Immunohistochemical analysis demonstrated diffuse positivity for pan-TRK and S-100 as well as partial expression of CD34. Next-generation sequencing confirmed the presence of the TRIM25::NTRK2 gene fusion. This case expands the morphological and genetic spectrum of NTRK-rearranged spindle cell tumors. Combined with its characteristic immunohistochemical and molecular pathological findings, this case provides insight into potential clinical therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: